Experimental cell therapy tested for Hard-to-Treat autoimmune conditions
NCT ID NCT07333118
Summary
This early-stage study is testing a new cell-based treatment called GT801 injection for people with moderate-to-severe autoimmune diseases that haven't responded to standard medications. The trial will enroll 22 adults with specific conditions like lupus, myositis, or scleroderma to first check if the treatment is safe and how the body processes it. Researchers will also look for early signs that it might help control these difficult diseases.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MODERATE TO SEVERE REFRACTORY AUTOIMMUNE DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Changzheng Hospital
RECRUITINGShanghai, Shanghai Municipality, 200003, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.